NetApp R&D decreased by 5.6% to $237.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.0%, from $247.00M to $237.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 3.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $221.00M | $210.00M | $216.00M | $220.00M | $235.00M | $240.00M | $243.00M | $230.00M | $243.00M | $247.00M | $262.00M | $249.00M | $271.00M | $252.00M | $257.00M | $247.00M | $256.00M | $242.00M | $251.00M | $237.00M |
| QoQ Change | — | -5.0% | +2.9% | +1.9% | +6.8% | +2.1% | +1.3% | -5.3% | +5.7% | +1.6% | +6.1% | -5.0% | +8.8% | -7.0% | +2.0% | -3.9% | +3.6% | -5.5% | +3.7% | -5.6% |
| YoY Change | — | — | — | — | +6.3% | +14.3% | +12.5% | +4.5% | +3.4% | +2.9% | +7.8% | +8.3% | +11.5% | +2.0% | -1.9% | -0.8% | -5.5% | -4.0% | -2.3% | -4.0% |